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ABSTRACT 
Lung diseases include some of the most widespread and deadly conditions known to affect people 
in the US today. One of the main challenges in treating lung disease is the difficulty of diagnosis. Clinical 
diagnosis remains largely dependent upon symptomatic-based diagnoses; many cases can be either 
misdiagnosed or undiagnosed until disease has progressed to a more severe stage. Most studies aimed at 
finding molecular-based diagnostics have focused on one or two diseases at a time, yielding limited 
success. Instead, we searched for biomarkers reflective of the global health state of the lung by studying 
data taken from a broad range of lung diseases. We used gene expression microarray data from five 
different lung diseases—lung adenocarcinoma, lung squamous cell carcinoma, large cell lung carcinoma, 
chronic obstructive pulmonary disease, and asthma—as well as a non-diseased phenotype, to train a 
classification tree scheme based on the Top Scoring Pair algorithm (Geman et al., Stat Appl Genet Mol 
Biol. 2004; 3: Article 19). The algorithm identified a 32 gene-pair panel that classified all of the 
phenotypes considered and another panel of 21 gene pair classifiers that classified the three cancers 
explicitly with sensitivity of 67±8% and 79±6% in ten-fold cross validation (p < 0.001), respectively. 
Several of the markers have been previously cited in literature as linked to these cancers. Thus, a TSP-
based classification tree scheme accurately identifies lung diseases from the relative expression of a 
parsimonious set of diagnostic gene pairs. 
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CHAPTER 1 
INTRODUCTION 
Lung diseases are some of the most pervasive and deadly diseases worldwide, causing over four 
million deaths each year [1]. In the US alone, asthma affects approximately 30 million people and is the 
most common chronic disease in children [2]. Chronic obstructive pulmonary disease (COPD), a 
progressive disease which causes difficulty breathing, affects about 16 million people and is the fourth 
leading cause of death worldwide [3]. Lung cancer is the most fatal cancer, leading to over 150,000 
deaths per year [4, 5].  
Currently, a main challenge of treating lung disease is the difficulty of diagnosis. In the case of 
asthma and COPD, late detection results in significantly reduced quality of life because the effects of the 
disease are not fully reversible. Most urgently, in the case of lung cancer, the tumor has often 
metastasized beyond the chest wall by the time of diagnosis. This late-stage diagnosis undermines the 
efficacy traditional treatments. Two-thirds of lung cancer patients are diagnosed at a late, metastatic, 
stage, which has a five-year survival rate of 2%, whereas 49% of patients diagnosed at the earliest stage 
can survive five or more years [5].  
A potentially valuable source of information to facilitate more effective diagnosis is the blood as 
it is comparatively non-invasive to sample and has been shown to contain organ-specific secreted gene 
products with concentrations that depend on disease state [5]. Despite the latent wealth of information 
found in blood, discovering viable blood markers for disease has so far yielded limited results. Although a 
handful of protein markers, including CA15-3, CEA, EGFR, and PAP have been used to aid clinical 
diagnosis of lung cancer, these markers have substantial false positive rates associated with noncancerous 
and non-diseased health states. The search for novel protein biomarkers with more favorable false 
positive rates is hindered by the fact that current proteomics methods cannot adequately survey and 
quantify the entire set of blood proteins, which have concentrations that range over at least nine orders of 
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magnitude [6]. Proteomics methods that attempt to systematically characterize as much of a biological 
sample as possible do not yield results as reliable as more targeted protein measurement techniques that 
quantify specific proteins of known identity. Therefore, a more effective biomarker discovery strategy 
might involve a two-phase procedure that involves discovering candidate sets of disease markers before 
further quantification on the protein level.  
We propose to identify likely blood marker candidates based on a meta-analysis of microarray 
data, which comprehensively quantifies gene expression on the mRNA level. To analyze these high-
throughput data, which include hundreds of measurements of tens of thousands of genes, we leverage 
computational algorithms to learn the relevant diagnostic signatures. Many studies in search of molecular 
diagnostics have been conducted on the genome scale, focusing on the expression levels of all human 
genes. These have typically focused on characterizing one disease compared to a control [7-9]. This 
strategy tends to yield limited long term success; few biomarkers survive through clinical trials. We 
attempt a holistic meta-analysis approach by collectively examining several lung associated phenotypes, 
both diseased and non-diseased, to find context specific biomarkers that are indicative of specific lung 
health states rather than general markers of presence or absence of disease.  
Previous analyses of multiple diseases have examined expression profiles across hundreds of 
genes which, although informative, are too numerous to serve as biomarker candidates for blood 
screening. An alternative approach based on the top scoring pair (TSP) algorithm [10], which classifies 
based on relative expression of a handful of genes. As this method predisposes the selection of a 
parsimonious set of classifiers, it is more desirable for identifying candidate gene markers of disease. 
Searching for likely blood markers with known identities facilitates targeted assays for more sensitive 
detection and quantification. We wish to harness a classification scheme based on TSP analysis to identify 
potential blood markers that can diagnose multiple lung diseases with high accuracy. We will examine 
data from five different lung disease phenotypes—the three types of non-small cell lung cancers: 
adenocarcinoma (ADC), squamous cell carcinoma (SCC), large cell lung carcinoma (LCLC); asthma 
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(AST); chronic obstructive pulmonary disease (COPD), and a non-diseased phenotype (NORM). Our 
meta-analysis will be based on the gene expression microarray data of tissue samples collected from 
human subjects from several different experimental studies. 
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CHAPTER 2 
METHODS 
2.1 Data Collection and Preprocessing 
We assembled lung related expression data from the publicly available online databases, Gene 
Expression Omnibus (GEO) and ArrayExpress. The heterogeneous sources of the data included in this 
meta-analysis introduce several aspects of variability among samples that are unrelated to the disease 
state. One of the main sources of variability stems from the fact that the data included in the study were 
originally collected from multiple experimental studies. These studies were performed by laboratories that 
sampled different geographical patient populations, collected and prepared the tissue samples using 
different methods, measured the gene expression using different microarray platforms, and utilized 
different data preprocessing methods to yield gene expression values from hybridization intensities 
measured by the microarrays. We attempted to minimize the sources of variability that were within our 
control. 
To reduce inter-platform variation, we included only lung-associated data that were collected 
from two Affymetrix (Santa Clara, CA, USA) oligonucleotide microarray platforms: 1) HG-U133 Plus 2, 
and 2) HG-U133A, which share a large number of common probes (22277) and have similar 
manufacturing procedures. These microarray platforms measure gene expression by quantifying the 
amount of gene-specific mRNA that is hybridized to ‘perfect match’ oligonucleotide probes that are 
complementary to the genes being measured. In addition to the ‘perfect match’ probes, the microarrays 
also have ‘mismatch’ probes, which have a mismatched nucleotide half way along the probe sequence. 
These mismatch probes attempt to estimate non-specific binding for the probes corresponding to each 
mRNA gene sequence. 
We investigated the effect of microarray preprocessing procedures on reported gene expression 
values and resulting classification, as described in Appendix A. The findings demonstrate that 
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preprocessing the raw hybridization intensities from different study batches together yielded reduced the 
resulting gene expression variability due to study batch source. To further mitigate the effects of study 
batch bias, we considered only phenotypes with data collected from at least two independent study 
batches, as labeled by the study labels provided by GEO or ArrayExpress, for our study. We used these 
data to train the classification algorithm and to test its performance. 
2.2 Disease Classification Algorithm 
Our classification scheme is based on a machine learning algorithm called top scoring pair (TSP) 
analysis, which analyzes ranked expression levels of samples for a binary phenotype classification [10]. 
The TSP algorithm finds a single gene pair that displays maximal relative expression reversal between 
samples of the two phenotypes, as assessed by:  
            |   ( )     ( )|, 
where 
   ( )   (              )  
is the probability that       has greater expression than       in patients of phenotype  . This 
probability is estimated when applied to experimental data by comparing the relative frequency of 
occurrence in patients with the known phenotype  . Gene pairs with high    ( ) for one phenotype and 
low    ( ) for the other (i.e., high TSP scores) have the desired relative expression reversal that facilitates 
definitive classification. Thus, the classifying gene pair with the highest TSP score is selected, and the 
classifying condition is: IF             THEN phenotype 1, ELSE phenotype 2. Figure 1 shows the 
relative expression of the classifying gene pair selected by TSP for the phenotypes AST and COPD. In 
this example,       (ITGB5) is always greater in expression than       (NUPL2) for AST patients, and 
the opposite is true for COPD patients. 
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Figure 1: Standard TSP classification output applied to AST and COPD patients. The relative expressions of the 
classifying gene pair are plotted on the axes. In this case, the relative expression of the gene ITGB5 is always greater 
than NUPL2 in AST, and the opposite is observed in COPD. 
The generalization of TSP, called k-TSP, selects a panel of   disjoint gene pair classifiers with 
the highest TSP scores, where   is a positive integer that can yield greatest classification sensitivity 
(            
                                             
                              
) [11]. We implement a variation of k-TSP, in which a 
test sample that has an expression profile such that an integer       of the gene pairs display the relative 
expression reversal indicative of phenotype 1 over phenotype 2 will be classified as phenotype 1. We 
select the parameter   to maximize the specificity while maintaining apparent sensitivity during training 
above a specified threshold. 
TSP and k-TSP perform binary classification. To classify more phenotypes, we structure a series 
of binary TSP classifications into a hierarchical classification tree. The tree is constructed by successively 
grouping together phenotypes with the most similar expression profiles as quantified by TSP score, 
resulting in an agglomerative hierarchical clustering dendrogram with the TSP score as the distance 
metric. The complete tree has all considered phenotype classes in the topmost node. Branches that 
7 
 
separate groups of phenotypes with the highest TSP score reside close to the top of the tree, and branches 
that separate groups with the lowest TSP score split at the bottom. 
The classification tree informs two methods of sequential TSP comparisons. The first, node-based 
method focuses on the nodes of each tree. The k-TSP variant method is applied, yielding panels of gene 
pair classifiers designed to determine whether or not test samples are members of the phenotypes that are 
grouped at each node. If a sample is affirmatively classified, then it passes through both branches 
spanning from the node and faces classification at both downstream nodes until it reaches nodes with only 
one phenotype. If a sample is not classified as belonging to one of the phenotypes at a node, then it is 
rejected from further classification at downstream nodes. This node-based classification can make 
multiple diagnoses because a sample could pass classification at multiple branches in the tree. 
Furthermore, rejection of a sample from being classified by the tree indicates that the sample does not 
appear to resemble any of the phenotypes in the tree. 
To break ties resulting from the node-based classification, a second, branch-based method is 
implemented. The branch-based classification compares groups on each left branch against groups on the 
corresponding right branch with the classic TSP classification approach, yielding one gene pair classifier 
per branch. If a sample is classified as belonging to a phenotype in the left branch node, then it is passed 
only down the branches that are downstream of the left node. Otherwise, the sample is passed down for 
subsequent classification at the branches downstream of the right node, akin to a decision tree with TSP 
as the decision metric.  
2.3 Disease Classification Scheme Parameter Selection 
The training of the TSP tree classification scheme involves examining the expression values of 
the genes that are selected as input to the algorithm. We adopted two primary strategies to refine the set of 
genes that were considered by the TSP tree scheme. 
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Our first gene refinement strategy involved examining the quality of the microarray expression 
measurements for each gene and each sample. The Affymetrix oligonucleotide microarrays standard data 
preprocessing protocol includes a function that assesses the expression value of each gene as ‘present,’ 
‘marginal’ or ‘absent’ based on whether or not the measured expression of the perfect match probes are 
significantly greater than the mismatch probes [12]. The ‘present’ call is made when the p-value of 
difference is less than 0.04, the ‘marginal’ call is made when the p-value of the difference is between 0.04 
and 0.06, and the ‘absent’ call is made when the p-value of the difference is greater than 0.06, 
representing no significant difference between the measurements of the perfect match and the mismatch 
probes. These expression quality calls can be used as a basis for filtering the expression probes to be 
considered in the classification scheme.  
 
Figure 2: Probe filtering effect on the number of genes excluded (dashed line) and the resulting sensitivities of the 
TSP tree classification averaged across the phenotypes tested (colored solid line). The error bars represent the 
standard deviation of the sensitivities averaged across the phenotypes. 
We investigated the effect of excluding expression probes that have ‘absent’ calls identified in a 
range of sample percentages on the resulting TSP tree classification performance. Figure 2 shows the 
performance of the TSP tree classification scheme as a function of the number of genes excluded from the 
algorithm’s consideration based on the number of ‘absent’ calls made for each gene. Although the number 
of genes excluded changes substantially depending on the threshold of ‘absent’ calls that are acceptable 
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for a gene to be considered in subsequent classification (ranges from 5818 to 21647 probes), the 
performance of the TSP tree classification scheme does not significantly change in the ‘absent’ call 
threshold. We chose to use a 90% absent exclusion threshold; ie., genes were excluded from consideration 
if more than 90% of the samples were labeled as ‘absent.’ 
Our second strategy for refining the set of genes to be considered by the classification algorithm 
is motivated by the long-term goal of finding diagnostic markers in the blood. To maximize the likelihood 
of finding classifiers that can be ultimately measured in the blood, we restricted the number of genes 
considered to those that code for proteins that have been reportedly found in the blood. We used a list of 
3020 peptides found in the blood by the HUPO plasma proteome project as the reference list [13], and 
found 2819 expression probes on the microarrays that code that overlap with the HUPO list. Out of these, 
2100 expression probes passed the absent call exclusion threshold and were considered in subsequent 
classification. 
2.4 Classification Scheme Performance Testing 
We subjected the classification scheme to a series of tests to assess the performance of the TSP 
tree classification performance. Our primary performance assessment involved executing a ten-fold cross 
validation with the data. The purpose of implementing cross validation is to test the performance of the 
classification scheme on data on which the algorithm was not trained, which mitigates the effect of over-
fitting and more closely approximates a clinically relevant test scenario. Cross validation is implemented 
by randomly excluding one tenth of the samples of each phenotype from the training data and by 
evaluating accuracy based on the classification of this excluded test set. The process is iterated ten times 
so that each excluded test set is disjoint. In order to maintain an approximately uniform distribution of 
phenotypes in the training dataset, we implemented a stratified cross validation wherein for each iteration 
of the outer loop, 58 ADC samples, 48 SCC samples and 47 NORM samples were included into the inner 
cross-validation to determine the training set. 
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We compared the performance of the TSP tree classification scheme with another popular 
machine learning classification algorithm, the support vector machine (SVM) [14]. We trained a one-vs.-
one multi-class SVM with a linear kernel on the disease data using the LIBSVM library for MATLAB 
[15]. We further implemented feature selection to choose the genes to be included in the analysis to be 
equal to the number of parameters selected from the TSP classifiers. The feature selection is based on the 
F-score metric [16], which is calculated for each gene   as [17]: 
 ( )  
∑ ∑  (    ) (   ̅̅̅̅    ̅)
 
                     
∑ ∑  (    ) (       ̅̅̅̅ )
 
                     
 
where   labels the total number of samples included in the analysis, and   labels the phenotypes to 
be classified. The     represents the expression of the  th gene in the  th sample, and the    represents the 
phenotype class of the  th sample. The terms    ̅̅̅̅  and   ̅ represent the mean expression level for a gene 
within a phenotype and across all phenotypes, respectively. The  ( ) represents the Kronecker delta 
function: 
 (    )   {
          
          
   
To test the significance of the TSP tree classification scheme performance, we randomly 
permuted the phenotype class labels associated with the expression data and trained the classification 
scheme on these permuted expression values 1000 times. We used the resulting distribution of 
sensitivities to estimate a p-value for the performance of the classification scheme derived from the un-
permuted data. 
To estimate the effect of experimental batch sources of variability on the data, we implemented a 
leave lab out validation, wherein the expression data from each experimental study was excluded from the 
training of the data and used to evaluate the performance of the classification algorithm. We also 
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investigated the effect of excluding multiple experimental studies from the training set on the resulting 
classification performance. 
2.5 Gene Classifier Interrogation 
As an additional, informal validation, we examined protein expression for the genes selected by 
the classification algorithms by visually inspecting immunohistochemistry (IHC) tissue stains the Human 
Protein Atlas (http://www.proteinatlas.org/) [18]. We compared the tissue stains of lung cancer and 
normal bronchial tissue for the genes in the lung cancer-associated classifier panels. 
We investigated the biological significance of the individual gene classifiers selected by the TSP 
tree classification algorithm by performing a literature search aided by the gene annotation compendium, 
Gene Cards (www.genecards.org) [19]. We investigated functional interactions between genes using the 
curated protein interaction database Metacore (Genego, St. Joseph, MI), which generated the interaction 
networks and provided the links to the literature substantiation. 
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CHAPTER 3 
RESULTS 
3.1 Overview of Data Collected 
We gathered lung disease related data from the publicly available online repositories: Gene 
Expression Omnibus (GEO) and ArrayExpress. Table 1 summarizes the gene expression microarray data 
collected, and Appendix B gives details about the studies and experimental procedures that generated 
these data. Each phenotype has data collected from three or more independent studies, with sample sizes 
ranging from 49 to 580.  
Table 1: This reports the number of samples, the number of studies, the types of platforms, and the method of tissue 
extraction used to collect the samples of the data included in the study. The platform labels represent 1) HG-U133 
Plus 2, and 2) HG-U133A.  
Disease Label Platforms # Studies 
# 
Samples 
Sample Type 
Adenocarcinoma ADC 1, 2 14 580 resection 
Squamous Cell Carcinoma SCC 1, 2 7 239 resection 
Large Cell Lung Carcinoma LCLC 1,2 4 49 resection 
Asthma AST 1 3 70 
airway epithelial 
brushing, broncho-
alveolar lavage 
Chronic Obstuctive 
Pulmonary Disease 
COPD 1,2 4 63 
airway epithelial 
brushing, resection 
Normal NORM 1,2 11 469 
airway epithelial 
brushing, resection 
A potential source of variability originates from the heterogeneity of sample collection methods. 
Cancer tissue samples were collected from surgical resection, whereas some COPD samples were 
collected from airway epithelial endoscopic brushings. AST samples were collected by brushing or by 
bronchoalveolar lavage. NORM samples consist of tissue collected from sudden death autopsy subjects as 
well as controls from studies that supplied the diseased tissue samples. The surgical resection control 
tissues collected in the studies generating the cancer-associated data were collected from patients with 
lung cancer locations distal to the tumor. 
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3.2 TSP Tree Classification Scheme Output for All Diseases 
We trained the TSP tree algorithm on these data, including both disease and non-disease 
phenotypes for consideration. In this paradigm, the top node does not have a classifier panel as all 
samples were assumed to belong to one of the six phenotypes. We used a sensitivity threshold of 98% for 
finding optimal  . Figure 3 shows the TSP tree algorithm output consisting of the classification tree and 
gene pair classifier panels. The vote integer   at each node is equal to 1 unless otherwise specified.  
 
Figure 3: TSP classification tree and gene pair markers. The tables associated with each node specify the node-
based classifiers. The diamond boxes show the branch-based classifiers. The classifiers consist of 32 gene pairs of 
54 unique genes.  
Notably, tree branching reflects phenotypic characteristics. For example, the lung cancers, ADC 
LCLC, and SCC, are first separated from the non-cancerous phenotypes before being separated from each 
other. Additionally of interest is the fact that several of the genes selected as classifiers by the algorithm 
have literature evidence suggesting a biological role in the associated diseases, demarcated in the figure 
by yellow or green boxes or text. This will be expounded further in Section 3.4. 
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Figure 4 compares ten-fold stratified ten-fold cross validation performance results of the TSP tree 
method against one-vs-one multiclass SVM with feature selection. The TSP tree method has an average 
sensitivity of 67±8%, which is comparable to the average performance of one-vs-one SVM: 66±6%. The 
TSP tree classifies lung disease expression data reasonably well, with 81% accuracy for SCC and COPD 
and at least 88% accuracy for the other three phenotypes. In contrast, classification sensitivity of LCLC 
and NORM samples is 46±10% and 52±10%, respectively. While these sensitivities are 2.8 fold better 
than chance and are comparable to the SVM performances, they are still suboptimal.  
 
Figure 4: Ten-fold cross validation results of TSP tree algorithm compared to one-vs-one SVM. The TSP method 
performs better in classifying most of the diseases and worse in classifying non-disease. 
The confusion matrix in  
Table 2 shows how samples of each phenotype are classified by the TSP tree algorithm. While 
overall precision (
             
                            
)  excluding rejection is 72±11%, the precision of LCLC and 
NORM samples is significantly poorer. LCLC samples have significant misclassification for ADC and 
SCC (20±9% each). NORM samples have significant false positive rates (20±7%) for COPD.  
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Table 2: The confusion matrix shows sample performance in ten-fold cross-validation. The rows represent the 
actual phenotype, and the columns represent the predicted phenotype. The values in the boxed cell is the fraction of 
a particular phenotype that was predicted to be a given phenotype (   (                     )) for 
  *                          + and     *                                 +. The 
       prediction represents samples that were not explicitly designated a phenotype by the classification 
algorithm. 
  
Predicted Phenotype 
 
  
ADC SCC LCLC AST COPD NORM REJECT 
 
A
ct
u
al
 P
h
en
o
ty
p
e
 
ADC 
0.66 
± 0.09 
0.04  
± 0.02 
0.11 
± 0.03 
0.002 
± 0.006 
0.02 
± 0.02 
0.07 
± 0.04 
0.11 
± 0.06 
58 
SCC 
0.05 
± 0.05 
0.72  
± 0.10 
0.10  
± 0.05 
0  
± 0 
0.02 
± 0.02 
0.02 
± 0.02 
0.09 
± 0.03 
47.8 
LCLC 
0.20 
± 0.09 
0.20  
± 0.09 
0.46  
± 0.10 
0  
± 0 
0.02 
± 0.02 
0.02 
± 0.02 
0.10 
± 0.04 
49 
AST 
0 
± 0 
0.001 
± 0.005 
0.004  
± 0.007 
0.95 
± 0.02 
0.01 
± 0.01 
0.01 
± 0.02 
0.03 
± 0.03 
70 
COPD 
0.02 
± 0.02 
0.01 
± 0.01 
0.01 
± 0.01 
0.01 
± 0.01 
0.72 
±0.07 
0.20 
± 0.07 
0.04 
± 0.04 
63 
NORM 
0.07 
± 0.04 
0.02 
± 0.02 
0.01  
± 0.02 
0.10 
± 0.03 
0.21 
± 0.09 
0.52 
± 0.10 
0.07 
± 0.04 
46.9 
  
55.2 47.7 35 72.3 58.6 43.3 22.6 334.7 
3.3 TSP Tree Classification Scheme Output for Non-Small Cell Lung Cancers 
Accounting for the difficulty in separating NORM from COPD, we constructed a second TSP tree 
that explicitly classifies only the cancer phenotypes (Figure 5).  
 
Figure 5: TSP tree classification scheme for lung cancers. The classifiers consist of 21 gene pairs of 37 unique 
genes.  
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Unlike the tree containing all phenotypes, classification is performed at the top node, which 
distinguishes whether a sample is one of the lung cancers considered or a non-cancer. Additionally of 
interest is the fact that several of the genes selected as classifiers by the algorithm have literature evidence 
suggesting a biological role in the associated diseases, demarcated in the figure by yellow or green boxes 
or text. This will be expounded further in Section 3.4. 
Figure 6 compares ten-fold cross-validation performance of the TSP cancer tree to one-vs-one 
SVM classification, and Table 3 reports the corresponding confusion matrix. Performance on non-cancer 
phenotypes is measured as the fraction of samples correctly rejected from further classification in the 
cancer tree.  
 
Figure 6: Ten-fold cross validation results of TSP cancer tree and SVM classification. 
The TSP tree method has an average sensitivity of 79±6%, which is comparable to the average 
performance of one-vs.-one SVM: 79±5%. The cancer tree rejects non-cancerous phenotypes with 
accuracies of 87-98±2%. The poorest overall performer, LCLC, has a sensitivity of 50±12% with the 
main sources of error deriving from misclassification as ADC or SCC with 21±9% and 20±6% 
respectively. This effect is possibly due to a shared non-small cell lung cancer signature. NORM has the 
greatest non-cancerous false rejection rate and is mistaken for ADC with 10±4% misclassification. This 
observation may be as a consequence of a significant number of NORM tissue samples being derived 
from adjacent non-cancer lung tissue resected from lung cancer patients. 
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Table 3: The confusion matrix shows sample performance in ten-fold cross-validation. The rows represent the 
actual phenotype, and the columns represent the predicted phenotype. The rows represent the actual phenotype, and 
the columns represent the predicted phenotype. The values in the boxed cell is the fraction of a particular phenotype 
that was predicted to be a given phenotype (   (                     )) for 
  *                          + and     *                                 +. The 
       prediction represents samples that were not explicitly designated a phenotype by the classification 
algorithm 
  
Predicted Phenotype 
 
  
ADC SCC LCLC REJECT 
 
A
ct
u
al
 P
h
en
o
ty
p
e
 
ADC 
0.70 
± 0.07 
0.04 
± 0.02 
0.11 
± 0.04 
0.15 
± 0.05 58 
SCC 
0.08 
± 0.05 
0.74 
± 0.09 
0.10 
± 0.07 
0.09 
± 0.06 47.8 
LCLC 
0.21 
± 0.09 
0.20 
± 0.06 
0.50 
± 0.12 
0.09 
± 0.05 49 
AST 
0.01 
± 0.01 
0.01 
± 0.02 
0.01 
± 0.01 
0.98 
± 0.02 70 
COPD 
0.05 
± 0.02 
0.005 
± 0.01 
0.01 
± 0.02 
0.93 
± 0.02 63 
NORM 
0.10 
± 0.04 
0.02 
± 0.02 
0.01 
± 0.01 
0.87 
± 0.04 46.9 
  
62.2 49.3 37.4 185.8 334.7 
Figure 7 shows the TSP tree classification performance when trained with label permuted data. 
The graph compares the distribution of the resulting sensitivities yielded from 1000 training iterations 
with the performance trained from actual data. The label permuted training data yielded sensitivities of 
36±28%, which is significantly different from the performance trained by un-permuted data (79±6%) with 
a p-value < 0.001. 
 
Figure 7: Histogram of the overall classification sensitivities resulting from 1000 label permutations. The red line 
indicates the overall classification sensitivity of the classification without label permutation. 
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Figure 8 shows the leave lab out validation performance results. The overall resulting sensitivities 
for the phenotypes are: 71±7% for ADC, 65±9% for SCC, 18±10% for LCLC, 71±26% for AST, 90±9% 
for COPD, and 89±11% for NORM. In general, we observe the trend that phenotypes with source data 
from many independent studies performed better than the phenotypes with source data from fewer source. 
For example, COPD has a greater average sensitivity than AST, and NORM has a greater accuracy than 
SCC, which in turn has a greater accuracy than LCLC. The main discrepancy in this trend is between 
LCLC and AST. This exception might be due to the fact that LCLC is substantially more similar to the 
other non-small cell lung cancers than AST is to NORM or COPD. 
 
Figure 8: TSP tree classification performance with leave lab out validation. The horizontal axis labels each 
experimental batch that was excluded from the training set. Each color represents the performance associated with a 
different phenotype. 
We further investigated the trend of increased number of source experimental batches leading to 
improved leave lab out validation performance by evaluating the classification performance resulting 
from excluding multiple labs from the training set. We tested the three phenotypes with more than 5 
independent experimental batches. Figure 9 shows the resulting sensitivities yielded from a range of the 
number of experimental batches excluded from the training to be used as the test sets. To compare 
between the three phenotypes, each of which has a different number of source experimental batches, we 
normalized the number of labs excluded as a percent of the total number of source studies in each 
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phenotype. The overall trend suggests a slight negative correlation between the number of labs excluded 
and the resulting sensitivities; all of the trendlines are have negative slopes. 
 
Figure 9: Leave multiple lab validation performance. The average overall classification sensitivity is plotted as a 
function of the fraction of total experimental studies excluded from the algorithm training step. The colored lines are 
trendlines estimated from linear regressions of the data from the respective phenotypes. 
To investigate the correspondence of gene expression level with protein level of the TSP cancer 
tree classifiers, we examined immunohistochemistry (IHC) stains for lung cancer from the Human Protein 
Atlas [18]. Figure 10 shows IHC stains of cancerous and non-diseased tissue for the gene pair classifiers 
from the (ADC SCC LCLC) node of the TSP cancer tree (Figure 5). Each image has cells stained blue to 
indicate the presence of the nuclei and brown to indicate the presence of the target protein. Visual 
inspection indicates that many gene pairs display the same relative expression profiles as predicted by 
TSP. In other words, the genes in the left column tend have greater protein expression, reflected in a more 
intense brown color, than the genes in the right column for the cancer stains. In contrast, genes in the right 
column have greater expression than those of the left column in the normal tissue stains. Note that several 
of these genes appear to be differentially expressed between cancer and normal tissue. This suggests that 
the gene pair markers selected by the TSP tree algorithm from gene expression data on the mRNA level 
might have similar predictive power when measured on the protein concentration level. 
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Figure 10: IHC stains of gene pair classifiers for the (ADC SCC LCLC) node from the TSP cancer classification 
tree. Brown indicates presence of protein and blue shows cell nuclei. Markers in each left column have greater 
expression than markers in the right columns in the TSP cancer tree method. Note that the COL5A2-FAM107A pair 
did not have IHC stain images available on the Human Protein Atlas. 
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3.4 Biological Significance of the Gene Classifiers 
The genes selected as classifiers by the TSP tree classification algorithm for both the all-
phenotype (Figure 3) and the cancer specific (Figure 5) cases have notable connections to the phenotypes 
they were selected to classify. 
In both the classification scheme for all diseases and the cancer-specific classification scheme, the 
algorithm selected several genes associated with cancer. For example, ABCC3, JUP, DSC3, and KRT5 
have been directly associated with their diagnostic phenotypes, ADC and SCC, respectively [20-23]. 
Similarly, LCN2 has been linked to cancer cell proliferation in ADC [24]. Other genes have been 
associated with cancers of relevant histologies in other parts of the human body. For instance, CAST, a 
classifier linked to high relative expression in ADC, has been linked to colorectal adenocarcinoma [25]. 
In contrast, PPL and CSF1R, classifiers linked to low relative expression in LCLC and ADC respectively, 
have been linked to esophageal and oral squamous cell carcinoma [26, 27].  
Besides these connections, other gene markers had reported links to lung cancer in general. For 
example, EGFR is linked to non-small cell lung cancer and has been used as a blood marker in the clinic 
for lung cancer [28, 29]. GSTM3 has been found to modulate susceptibility to smoking-related lung 
cancer [30]. TPI was linked to lung cancer in an in vitro carcinogenesis model [31]. These genes were 
selected as classifiers linked to low relative expression in AST and COPD, which makes sense because a 
significant portion of the data that the algorithm is seeking to reject at the AST and COPD nodes is lung 
cancer data. 
Several other genes in the classification schemes have been associated with cancer-associated 
processes. For example, TRAP1, a marker linked to high relative expression in LCLC, is an apoptosis 
inhibitor in lung cancer [32]. Furthermore, inhibition of KIF11, a classifier linked to the (ADC LCLC) 
node, is associated with reduced tumor growth and is [33]. Indirect cancer associations are also found in 
the COPD panel. For example, alterations of the acetylated HIST4H4, a low relative expression COPD 
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marker, have been attributed to decrease in protein levels of the transcription factor c-Myc, which 
contributes to regulating cell cycle progression, apoptosis, and cellular transformation under hypoxic 
conditions [34, 35]. 
The classification trees also isolated genes associated with inflammation in relevant markers. In 
particular, MRC1, a marker selected as having low relative expression in ADC, LCLC, and SCC, has 
been linked to inflammatory response by mediating ligand binding and endocytosis of macrophages [36], 
probably because a significant portion of the data that the algorithm is seeking to reject at the cancer node 
is AST and COPD data. Additionally, the positive COPD and negative NORM marker CAMK2G has 
been linked to airway inflammation, which is one of the pathophysiological effects of COPD [37]. 
In addition to isolating individual classifiers that have biological relevance to the target 
phenotypes, the classification trees also selected gene pairs that have functional interactions associated 
with the phenotypes. The first two examples are classifier pairs in the ADC and LCLC panels from the all 
phenotypes classification scheme. TRIM28 is a corepressor that contributes to the inactivation of the 
tumor suppressor p53 [38]. IQGAP1 had expression in the cell membrane that was previously found to be 
inversely correlated with E-cadherin, in gastric cancers, which contributes to tumor cell migration [39]. 
Increased expression of DNMT1 results in hypermethylation of tumor suppressor gene promoters and 
subsequent inhibition of these genes, and has been shown to correlate with poor prognosis in lung cancer 
patients [40]. NOTCH2 is contributes to a signaling pathway that induces apoptosis, which is linked to a 
classifier that has low relative expression in LCLC. Interestingly, IQGAP1 and TRIM 28 are linked by 
molecular interaction, as are DNMT1 and NOTCH2, as illustrated in Figure 11. IQGAP1 has been found 
to activate ERK1 by binding, which serves to propagate the MAPK cascade to regulate cellular processes 
including proliferation, differentiation, and cellular signals [41] and has been shown to play a role in lung 
cancer cell lines [42, 43]. ERK1 in turn phosphorylates TRIM28 with undetermined effect [44]. DNMT1 
transcriptionally inhibits the transcriptional factor ESR1 [45], which is primarily responsible for 
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regulating cellular growth and differentiation in reproductive organs but has also been found to be 
expressed in ADC [46]. ESR1 in turn transcriptionally activates NOTCH2 [47]. 
 
Figure 11: Interaction network associated with the ADC node of the all phenotype TSP tree (Figure 5). The 
classifiers are circled in blue. The interaction of IQGAP1 and TRIM28 (i.e., TIF1-beta) is linked by ERK1/2 
(highlighted in pink), and the interaction of DNMT1 and NOTCH2 are linked by ESR1 (highlighted in blue). 
Network representation is generated by Metacore (Genego, St. Joseph, MI). The highlighted interactions are also 
observed in the LCLC node. 
In addition, the genes COL3A1 and EPAS1 are linked by molecular interaction via MMP14 
(Figure 12). EPAS1, which has been associated with oxygen homeostasis and angiogenesis in cancer [48, 
49], has been shown to transcriptionally activate MMP4 under hypoxic conditions [50]. MMP14 in turn 
inhibits COL3A1 by cleaving the collagen into peptide fragments [51]. The linking gene MMP14 has 
been shown to be differentially expressed in non-small cell lung cancer compared to normal lung tissue 
[52], and has been linked to tumor cell migration and metastasis by participating in the invasion of the 3D 
extracellular collagen matrices [53]. 
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Figure 12: Interaction network associated with the (ADC LCLC SCC) node of the cancer specific TSP tree (Figure 
5). The classifiers are circled in blue. The interaction of COL3A1 (i.e. collagen III) and EPAS1 is linked by MMP14 
(highlighted in blue). Network representation is generated by Metacore (Genego, St. Joseph, MI). 
Examination of the gene pair classifiers derived from the TSP classification scheme suggests 
putative biological links between the classifiers and the phenotypes being classified. 
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CHAPTER 4 
DISCUSSION 
We have developed a lung disease diagnosis scheme based on a meta-analysis of gene expression 
microarray data. The meta-analysis across many experimental studies and hundreds of samples was 
facilitated by a novel consensus preprocessing of the raw microarray intensity measurements to reduce 
experimental batch-associated variability. We developed two classification schemes: a generic classifier 
which explicitly diagnoses all of the phenotypes considered and a cancer-specific classifier which only 
explicitly diagnoses the three non-small cell lung cancer phenotypes. This all-phenotype tree classifies 
phenotypes with significant accuracy that was comparable to performance with one-vs.-one SVM, but it 
has substantial misclassification from NORM samples as being classified as AST or COPD. This might 
be because a substantial number of NORM samples were non-cancerous tissue taken from lung cancer 
patients. These subjects might have had undocumented COPD or AST. Also, a significant number of 
samples were controls from studies examining AST and COPD. COPD and AST had comparatively few 
numbers of samples and independent studies undertaken, which potentially allows for a lab-specific 
signature to dominate the expression profiles. Given the difficulty separating NORM from COPD and 
AST, we chose to focus on the lung cancers. 
The cancer-specific tree scheme explicitly diagnoses only the cancer phenotypes and rejects non-
cancers from classification. This cancer tree classifies the phenotypes examined with comparably to one-
vs.-one SVM with good accuracy on all phenotypes except LCLC. We surmise that the misclassification 
of LCLC might be due to a combination of the molecular similarity of LCLC with ADC and SCC—
making it a harder classification problem than AST vs. ADC, for example—in concert with the relative 
dearth of data available compared to the other phenotypes. Leave-lab-out validation substantiates the 
premise that improved increasing the amount of training data available from more diverse set of 
experimental studies results in improved classification efficacy by showing a negative correlation 
between the accuracy and the number of independent studies available to train the classification 
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algorithm. Encouragingly, immunohistochemistry stains showed that the gene products of many 
classifiers display similar relative concentrations to those predicted by TSP, which substantiates the 
possibility that these classifiers have diagnostic protein concentration profiles in the blood. 
Interestingly, several classifiers isolated by the algorithm can be biochemically linked to their 
disease phenotypes in literature. This suggests that there might be an underlying biological reason why 
the gene pairs are diagnostic. We plan to examine further the potential biological significance of 
classifiers, especially in the context of probing the underlying gene and protein networks that are 
perturbed by disease. 
We have taken a first step toward finding diagnostic blood markers for lung disease. Guided by 
the lists of gene pairs inferred from the TSP tree algorithm, we can target sensitive assays to quantify 
protein levels of promising classifiers in the blood. If a set of blood markers can demonstrate predictive 
reproducibility, these can be harnessed as a platform to aid effective diagnosis and presymptomatic 
screening of disease. Moreover, elucidating the potential contributions of the markers to disease-inducing 
perturbations might bring greater insight into underlying mechanisms of the diseases and inform a closer 
monitoring of disease states. Thus, markers potentially have diagnostic utility to aid effective early 
screening of patients and to assess the state of diseases through its progression and through treatments. 
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APPENDIX A: COMPARISON OF MICROARRAY PRE-PROCESSING TECHNIQUES 
 
The gene expression microarray data measures intensity of fluorescently labeled gene fragments 
that are bound to sets of oligonucleotide probes with specific sequences tailored to be complementary to 
the target genes. The raw measurement for each gene is a set of intensities for each set of probes, which 
require in silico preprocessing to reconcile into a single expression value. The integration of the data 
involves correcting for background variability, normalizing the intensities, and summarizing the set of 
probes into a single value. Several preprocessing methods have been developed by multiple sources to 
perform this analysis; Table 4 summarizes the features of the three methods that were applied to the data 
by the experimental studies included in this meta-analysis. 
Table 4: Description of three gene expression microarray preprocessing procedures, as adopted from [54]. Each of 
these procedures have distinct approaches to the background correction, normalization, and summarization steps. 
Procedure 
Background correction 
Method 
Normalization 
Method 
Summarization 
Method 
Reference 
MAS5 
Full or partial mismatch 
probe subtraction 
Constant 
parameter 
Tukey biweight [55] 
RMA 
Signal and noise close-
form transformation 
Quantile Median polish [56] 
GCRMA 
Optical noise, probe 
affinity and mismatch 
probe adjustment 
Quantile Median polish [57] 
We studied the effect of including data processed with different procedures the resulting 
expression values reported as well as and its effect on TSP classification performance on a small test 
subset of the meta-analysis data. The test set incorporated data from ADC (77 samples from GSE10245, 
GSE17475, and GSE10799) and SCC (75 samples from GSE10245, GSE2109, and GSE6253). The raw 
intensity files were compiled and preprocessed each sample with RMA and GCRMA using MATLAB. 
We subsequently assembled datasets composed of different mixtures of preprocessing methods (ie.: 0%, 
25%, 50%, 75%, 100% RMA preprocessing) and compared the performance of standard binary TSP. 
output of binary TSP using input of data with mixed preprocessing method. For each input dataset 
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containing both RMA and GCRMA preprocessed data, we tested 20 dataset splicing permutations that 
preserved the RMA/GCRMA ratio. 
Figure 13 shows the ten-fold cross validation performance of the binary TSP classification as a 
function of the fraction of samples that were preprocessed with RMA. The accuracy of the binary TSP 
classification is substantially undermined by including datasets generated by heterogeneous preprocessing 
methods. Interestingly, datasets preprocessed consistently yielded comparable accuracies independent of 
the preprocessing method selected. 
 
Figure 13: Performance of binary TSP classification at different RMA/GCRMA preprocessing ratios. The error bars 
represent the standard deviation from 20 permutations. 
We investigated a potential cause for this difference in classification performance. Figure 14 
illustrates the distribution of the gene classifiers selected by TSP during different rounds of training. The 
TSP algorithm selected classifiers much more consistently for datasets containing pure RMA and pure 
GCRMA than for datasets containing mixed RMA and GCRMA, which show almost a uniform 
distribution of gene selection. This suggests that different preprocessing methods transform the data in 
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different ways, so that mixing preprocessing procedures introduces a source of non-phenotype associated 
variability. Applying a single preprocessing procedure consistently mitigates this effect. 
 
Figure 14: Distribution of classifiers selected by TSP in different iterations of training. The horizontal axis is the 
gene label and the vertical axis is the frequency that any particular gene were chosen. 
Although the RMA and GCRMA preprocessed sets yielded comparable accuracy, we wished to 
determine whether there is substantial difference in selecting one preprocessing method over the other. 
Table 5 reports the top ten classifier pairs selected by the TSP algorithm based on input data processed 
only by RMA and only by GCRMA, respectively. There is little overlap between the classifiers selected 
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in two preprocessing sets; only 5 out of the 20 genes are in common, and none of the gene pairs are 
preserved across the two sets. 
Table 5: Top ten TSP classifier gene pairs selected based on data from RMA and GCRMA consensus 
preprocessing, respectively. The genes colored blue and underlined have literature references associated with the 
relevant phenotype. 
 
Because we wished to assess which of the two preprocessing methods is more favorable for the 
purpose of the meta-analysis, we compared the literature associations with each gene on the two gene 
lists. We found that the GCRMA list had substantially more genes that had literature references associated 
to the relevant phenotype (ADC in the case of the        column, SCC in the case of the        column), 
which are demarcated in the table as the boxes highlighted in green or yellow. Therefore, we elected to 
use the GCRMA method in MATLAB to preprocess all of the data included in the meta-analysis. 
Figure 15 compares the effect of consistent versus non-consistent preprocessing on the variance 
in the entire meta-analysis dataset as measured by principal component analysis. Panel A and C show the 
data preprocessed differently by each experimental study, and panels B and D show the data preprocessed 
consistently by GCRMA in MATLAB. 
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Figure 15: Principal component analysis of the lung-associated gene expression data post consensus preprocessing. 
The first two principal components are shown. In panels A and B, the colors denote different phenotypes, whereas in 
panels C and D, the different colors denote different experimental batch. 
Visual inspection suggests that in both the consistent preprocessing and the study specific 
preprocessing cases, the data tend to be separated by experimental study more prominently than by 
phenotype. However, consistent preprocessing substantially reduces the variation associated with batch 
effects. 
A B 
C D 
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APPENDIX B: DETAILED OVERVIEW OF EXPERIMENTAL DATA INCLUDED IN META-
ANALYSIS 
 
Table 6: Description of the experimental studies from which the data included in the meta-analysis were derived. 
The ‘Study Label’ column designates the GEO or ArrayExpress study identification numbers. The ‘GPL’ column 
designates the microarray platform used to take the expression measurement, as labeled by GEO (GPL570 
represents HG-U133 Plus 2, and GPL96 represents HG-U133A). The bolded, boxed numbers in the ‘Samples’ 
column report the total number of samples for each phenotype. 
 
Table 6 (cont.) 
Phenotype 
Study 
Label 
GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Pre-
processing 
Method 
Notes 
Asthma 
(AST) 
GSE7368 570 6 
Goleva 
(no paper) 
broncho-
alveolar 
lavage 
cells 
phenol chloroform 
isoamyl alcohol 
extraction 
ethanol pre-
cipitation recovery, 
Qiagen RNeasy Kit 
purification 
Expression 
Analysis 
Technical 
Manual of 
Affymetrix. 
MAS5.0 
steroid 
resistant vs 
steroid 
succeptible 
subgroups 
 
GSE4302 570 55 [58] 
airway 
epithelial 
brushing 
NuGen Ovation 
RNA 
amplification 
2.75ug cRNA, 
16 hr, 45C, 
Affymetrix 
Fluidics 
Station 450 
RMA  
(Bioconductor)  
 
GSE18965 96 9 [59] 
airway 
epithelial 
brushing 
Qiagen RNeasy 
Kit 
15ug cRNA, 
16 hr, 45C, 
Affymetrix 
Fluidics 
Station 450 
GCRMA  
(Bioconductor) 
cells were 
cultured for 
24 hours 
before 
RNA 
extraction 
   
70 
      
Chronic 
Obstructive 
Pulmonary 
Disease 
(COPD) 
GSE5058 570 15 [60, 61] 
airway 
epithelial 
brushing 
trizol extraction, 
Qiagen RNeasy 
Kit purification 
Expression 
Analysis 
Technical Manual 
15ug cRNA, 
16 hr, 45C, 
Affymetrix 
Fluidics 
Station 450 
RMA 
 
 
GSE8545 570 15 [62] 
airway 
epithelial 
brushing 
trizol extraction, 
Qiagen RNeasy 
Kit 
Expression 
Analysis 
Technical Manual 
15ug cRNA, 
16 hr, 45C, 
Fluidics 
Station 450 
RMA 
 
 
GSE8581 570 15 [7] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual 
20ug cRNA 
45C overnight, 
450 Fluidics 
Station 
MAS5.0 
 
 
GSE1650 96 18 [63] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Superscript II 
reverse trans-
criptase, oligo dT 
primer, T7 RNA 
pol promoter, 
ENZO Bioarray 
RNA transcript 
labeling kit, 
Qiagen RNeasy 
Kit purification 
8-10ug cRNA, 
overnight, 
Agilent 
confocal laser 
scanning 
RMA 
emphysema 
only 
   
63 
      
Adeno-
carcinoma 
(ADC) 
GSE10245 570 40 [64] 
resection, 
snap 
frozen 
tumor 
Qiagen RNeasy 
Kit 
Expression 
Analysis 
Technical 
Manual. 
GCRMA 
(Bioconductor)  
GSE17475 96 28 [65] 
resection, 
snap 
frozen 
tumor 
Qiashredder, 
Qiagen RNeasy 
Kit  RNA 
extraction 
Expression 
Analysis 
Technical 
Manual. 
MAS5.0 
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Table 6 (cont.) 
Phenotype 
Study 
Label 
GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Pre-
processing 
Method 
Notes 
Adeno-
carcinoma 
(ADC) 
GSE10799 570 16 [66] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual 
protocol 
50ng cRNA, 
16hr 45C, 
Fluidics 
Station 450 
stain, 
GeneChip 
Scanner 7G 
GCRMA 
stromal cell 
content: 
<30%, 
MAIME 
standards 
followed 
 
GSE7670 96 27 [67] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual 
MAS5.0 
 
 
GSE10072 96 58 [68] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Qiagen RNeasy 
Kit,  
Expression 
Analysis 
Technical Manual 
Expression 
Analysis 
Technical 
Manual  
RMA 
(Bioconductor)  
 
GSE12667 570 75 [69] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5 
>70% 
tumor cell 
 
GSE3141 570 58 [70] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual 
MAS5 
 
 
GSE2109 570 61 [71] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual 
protocol 
Expression 
Analysis 
Technical 
Manuall 
MAS5 
 
 GSE19188 570 45 [72] 
resection, 
snap 
frozen 
tumor 
trizol extraction,  
Qiagen RNeasy 
Kit, 
Expression 
Analysis 
Technical Manual 
20ug cRNA 
16hr 45C, 450 
Fluidics 
Station, 
GeneChip 
Scanner 3000 
RMA 
 
 
GSE18842 570 14 [73] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
protocol 
Expression 
Analysis 
Technical 
Manual  
protocol 
RMA 
 
 
GSE14814 96 28 [74] 
resection, 
snap 
frozen 
tumor 
guanidium 
isothiocyanate 
solution 
homogenization, 
acid phenol-
chloroform 
extraction 
Expression 
Analysis 
Technical 
Manual   
RMAexpress 
v0.3  
 
E-TABM-
15 
96 23 
Blum  
(no paper) 
resection, 
snap 
frozen 
tumor 
Superscript ds-
cDNA synthesis 
kit,  
ENZO Bioarray hi 
yield RNA 
transcript labeling 
kit,  
Qiagen RNeasy 
Kit purification 
Expression 
Analysis 
Technical 
Manual, 
Fluidics 
Station 
Protocol 
MAS5.0 
 
 
E-MEXP-
231 
96 49 [75] 
resection, 
snap 
frozen 
tumor 
GeneChip 
Expression 
Analysis 
Technical Manual 
protocol 
GeneChip 
Expression 
Analysis 
Technical 
Manual 
protocol 
MAS5.0 
Tumor 
content: 
>70% 
GSE10445 570 59 [76] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual  
RMA 
 
   
580 
      
Squamous 
Cell 
Carcinoma 
(SCC) 
GSE10245 570 18 [64] 
resection, 
snap 
frozen 
tumor 
Qiagen RNeasy 
Kit purification 
Expression 
Analysis 
Technical Manual 
 
Expression 
Analysis 
Technical 
Manual 
GCRMA  
(Bioconductor) 
controls 
were qPCR 
verified 
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Table 6 (cont.) 
Phenotype 
Study 
Label 
GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Pre-
processing 
Method 
Notes 
Squamous 
Cell 
Carcinoma 
(SCC) 
GSE6253 96 18 [77] 
resection, 
snap 
frozen 
tumor 
flash frozen 
standard protocol, 
1-5ug RNA used 
Expression 
Analysis 
Technical 
Manual   
RMA 
 
 
GSE3141 570 53 [70] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual 
MAS5 
 
 
GSE2109 570 40 [71] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5 
 
 
GSE19188 570 27 [72] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
20ug cRNA 
16hr 45C, 450 
Fluidics 
Station, 
GeneChip 
Scanner 3000 
RMA 
 
 
GSE18842 570 32 [73] 
resection, 
snap 
frozen 
tumor 
Qiagen RNAeasy 
Mini Kit 
extraction 
Expression 
Analysis 
Technical Manual   
Expression 
Analysis 
Technical 
Manual   
RMA 
 
 
GSE14814 96 52 [74] 
resection, 
snap 
frozen 
tumor 
guanidium 
isothiocyanate 
solution 
homogenization, 
acid phenol-
chloroform 
extraction 
Expression 
Analysis 
Technical 
Manual  
protocol 
RMAexpress 
v0.3  
   
239 
      
Large Cell 
Carcinoma 
(LCLC) 
GSE2109 570 7 [71] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5 
 
 
GSE19188 570 19 [72] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
20ug cRNA 
16hr 45C, 450 
Fluidics 
Station, 
GeneChip 
Scanner 3000 
RMA 
 
 
GSE14814 96 10 [74] 
resection, 
snap 
frozen 
tumor 
guanidium 
isothiocyanate 
solution 
homogenization, 
acid phenol-
chloroform 
extraction 
Expression 
Analysis 
Technical 
Manual   
RMAexpress 
v0.3  
 
GSE10445 570 13 [76] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
RMA 
 
   
49 
      
Normal 
(NORM) 
GSE1643 570 40 [78] 
resection, 
snap 
frozen 
tissue 
Qiagen MiniElute 
protocol 
extraction, 
ENZO Affymetrix  
cRNA synthesis 
Expression 
Analysis 
Technical 
Manual  
protocol 
GCRMA 
lung tissue 
from organ 
transplant 
donors, 
 
GSE994 96 75 [79] 
airway 
epithelial 
brushing 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5.0 
 
 
GSE3320 96 11 [80] 
airway 
epithelial 
brushing 
trizol RNA 
extraction, 
Expression 
Analysis 
Technical Manual 
Expression 
Analysis 
Technical 
Manual   
MAS5.0, 
RMA  
 
GSE4302 570 44 [58] 
airway 
epithelial 
brushing 
NuGen Ovation 
RNA 
amplification 
2.75ug cRNA, 
16 hr, 45C, 
Fluidics 
Station 450 
RMA 
(Bioconductor)  
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Table 6 (cont.) 
Phenotype 
Study 
Label 
GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Pre-
processing 
Method 
Notes 
Normal 
(NORM) 
GSE18965 96 7 [59] 
airway 
epithelial 
brushing 
Qiagen RNeasy 
Kit extraction 
15ug cRNA, 
16 hr, 45C, 
Fluidics 
Station 450 
GCRMA 
(Bioconductor) 
cells were 
cultured for 
24 hours 
before 
RNA 
extraction 
 
GSE5058 570 24 [60, 61] 
airway 
epithelial 
brushing 
trizol extraction, 
Qiagen RNeasy 
Kit purification,  
Expression 
Analysis 
Technical Manual  
15ug cRNA, 
16 hr, 45C, 
Fluidics 
Station 450 
RMA 
 
 
GSE8545 570 16 [62] 
airway 
epithelial 
brushing 
trizol extraction, 
Qiagen RNeasy 
Kit purification,  
Expression 
Analysis 
Technical Manual  
15ug cRNA, 
16 hr, 45C, 
Fluidics 
Station 450 
RMA 
 
 
GSE8581 570 19 [7] 
resection, 
snap 
frozen 
tissue 
Expression 
Analysis 
Technical Manual  
20ug cRNA 
45C overnight, 
450 Fluidics 
Station 
MAS5.0 
 
 
GSE1650 96 12 [63] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Superscript II 
reverse trans-
criptase, oligo dT 
primer, T7 RNA 
pol promoter, 
ENZO Bioarray 
transcript 
labeling, Qiagen 
RNeasy Kit 
purification 
8-10ug cRNA, 
overnight, 
Agilent 
confocal laser 
scanning 
RMA 
 
 
GSE10799 570 3 [66] 
resection, 
snap 
frozen 
tissue 
Expression 
Analysis 
Technical Manual 
protocol 
50ng cRNA, 
16hr 45C, 450 
Fluidics 
Station stain, 
GeneChip 
Scanner 7G 
GCRMA 
 
 
GSE7670 96 27 [67] 
resection, 
snap 
frozen 
tissue 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5.0 
 
GSE10072 96 49 [68] 
resection, 
snap 
frozen 
tissue 
trizol extraction, 
Qiagen RNeasy 
Kit purification, 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual 
RMA 
(Bioconductor)  
 
GSE19188 570 65 [72] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
20ug cRNA 
16hr 45C, 450 
Fluidics 
Station, 
GeneChip 
Scanner 3000 
RMA 
 
 
GSE18842 570 45 [73] 
resection, 
snap 
frozen 
tumor 
Qiagen RNAeasy 
Mini Kit 
extraction 
Expression 
Analysis 
Technical 
Manual   
RMA 
 
 
E-TABM-
15 
96 18 
Blum  
(no paper) 
resection, 
snap 
frozen 
tumor 
Superscript ds-
cDNA synthesis 
kit, ENZO 
Bioarray hi yield 
RNA transcript 
labeling kit, 
Qiagen RNeasy 
Kit purification 
Expression 
Analysis 
Technical 
Manual, 
Fluidics 
Station 
Protocol 
MAS5.0 
 
 
E-MEXP-
231 
96 9 [75] 
surgical 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical 
Manual, GNF 
Fluidics station 
cDNA synthesis 
GeneChip 
Expression 
Analysis 
Technical 
Manual 
protocol 
MAS5.0 
 
   
469 
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